 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who's Online | |
There are currently, 57 guest(s) and 10 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | PRISMS Crossover Study Corroborates Benefit of Rebif as Treatment for RRMS |
 The PRISMS study, demonstrating the efficacy of Rebif, was completed in
2001. It demonstrated benefits in all outcome measures across the 2
year trial, particularly with respect to number of relapses, MRI
activity and disability progression. As with all major trials, there
was a placebo group, which provided the PRISMS study an interesting
opportunity to investigate what would happen if the patients originally
on placebo were then switched over to Rebif therapy. The results are
consistent with what one might expect:
Beginning in the third year (after two years of placebo), the placebo
patients were randomized into two groups, one receiving 22mcg, the
other 44 mcg, subcutaneously 3 times per week. At the end of years 3
and 4, the patients were evaluated, and both groups showed a 54%
reduction in mean relapse rate, as well as a "significant" improvement
in disability progression, MRI activity and T2 lesion burden.
Again this is nothing surprising-- because the patient group was well
understood in this study prior to inception of therapy, the results are
slightly more striking (e.g., instead of comparing a patient to an
average relapse rate expected of an RRMS'er, you can compare the
patient directly to their own relapse rate in the previous years).
The studies continue to corroborate that the Interferons do indeed work as disease modifying agents...
Click "read more" for the link to the abstract on PubMed...
Advertisement
Article Abstract Hosted at PubMed
Click here
|
|
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Related Links | |
| Article Rating | |
| Options | |
|
|
|
